Hidden Bargains: Why These 'Expensive' Pharma Stocks Are Actually Undervalued

$ABBV and $CVS appear to be trading at prohibitively expensive valuations based on conventional metrics, with trailing price-to-earnings multiples exceeding 100 and 42 respectively. Yet beneath these alarming surface-level figures lies a compelling investment thesis: both pharmaceutical and healthcare companies are actually trading at attractive valuations when adjusted for one-time charges that artificially suppressed their most recent earnings reports. For value-conscious investors willing to dig deeper, these names represent significant opportunities in a sector facing structural headwinds.

The disconnect between trailing and forward valuations tells the real story. When examined through a normalized lens—accounting for non-recurring charges that temporarily depressed earnings—AbbVie's forward P/E multiple collapses to just 15, while CVS Health trades at a forward P/E of 13. These multiples position both companies well below their historical averages and significantly cheaper than the healthcare sector median, suggesting meaningful undervaluation in current market pricing.

The Earnings Distortion Problem

Trailing P/E multiples have become increasingly unreliable for companies facing temporary operational disruptions or one-time accounting events. Both $ABBV and $CVS have experienced just such circumstances in recent periods:

• AbbVie has contended with significant non-recurring charges related to business restructurings and acquisition integration costs
• CVS Health similarly faced one-time expenses that depressed its most recent earnings per share figures
• These charges created a misleading perception of valuation expense that doesn't reflect normalized operating performance

When these temporary items are excluded from earnings calculations, the resulting forward multiples present a dramatically different investment picture. A forward P/E of 15 for AbbVie and 13 for CVS represent valuations that would typically attract institutional investors and active value managers, particularly in mature healthcare sectors where growth is predictable but steady.

The pharmaceutical industry has historically commanded modest forward multiples in the 12-18 range, reflecting modest but consistent earnings growth and mature market dynamics. AbbVie's forward multiple of 15 sits comfortably within this range, while CVS's 13 actually trades below historical sector averages, despite the company's diversified healthcare platform spanning pharmacy benefits management, retail pharmacy, and health insurance operations through its Aetna subsidiary.

Market Context: Healthcare Valuation Dynamics

The broader healthcare sector faces a complex backdrop that has pressured valuations across pharmaceutical and healthcare services companies. Several structural factors help explain why both $ABBV and $CVS have traded down to levels that create value opportunities:

Sector Headwinds: The healthcare industry has contended with regulatory uncertainty around drug pricing, particularly in the context of congressional pressure to rein in pharmaceutical costs. This regulatory environment has kept investor sentiment cautious, with many healthcare equities trading at depressed multiples relative to their fundamentals.

Dividend Appeal: Both companies offer compelling dividend yields that have become increasingly attractive as fixed-income yields have normalized from historic lows. AbbVie and CVS Health maintain solid dividend payouts, making them attractive for income-focused portfolios in an environment where bond yields no longer guarantee returns. These dividend yields provide downside protection while investors wait for multiple expansion.

Competitive Landscape: In pharmaceuticals, AbbVie faces competition from increasingly affordable biologics and generic alternatives, pressuring pricing power. However, the company maintains a strong pipeline and established market positions in key therapeutic areas. CVS Health, meanwhile, operates in the highly competitive pharmacy benefits management (PBM) space, competing with $LRCX peers like UnitedHealth's Optum and Express Scripts. Despite competitive pressures, both companies maintain significant market share and switching costs that protect their business models.

Earnings Normalization: As companies move past the one-time charges that depressed recent results, forward earnings will gradually catch up to their normalized run rates. This process typically drives multiple expansion as investors regain confidence in predictable earnings power. The gap between trailing and forward multiples creates a natural timeline for valuation recovery.

Investor Implications: Why This Matters Now

For equity investors, the distinction between trailing and forward valuations represents one of the most consequential analytical challenges in security selection. Markets occasionally overshoot on negative news, creating opportunities for disciplined investors who can distinguish temporary noise from fundamental deterioration.

Valuation Recovery Potential: The current pricing of $ABBV and $CVS likely reflects worst-case assumptions about future earnings. As normalized earnings become evident in forward periods, forward multiples should expand toward sector averages. If AbbVie simply trades at a 17 forward multiple (still below historical averages) rather than 15, the stock could appreciate 13% before earnings even grow. This multiple expansion, layered on top of organic earnings growth, creates a compelling risk-reward profile.

Income Generation: Both stocks' dividend yields provide meaningful current income while investors wait for multiple expansion. This combination of current yield and capital appreciation potential appeals to core portfolio holdings and income-focused strategies.

Balance Sheet Strength: Despite temporary earnings pressures, both AbbVie and CVS Health maintain solid balance sheets and cash generation capabilities. This financial strength protects dividend payments and provides flexibility for strategic investments or share buybacks that could further support equity valuations.

Sector Rotation: If healthcare valuations begin to normalize following regulatory clarity or market sentiment shifts, both names could benefit disproportionately given their current relative undervaluation. Portfolios with underweight healthcare exposure may find value here before the broader market recognizes the opportunity.

Forward Outlook

The fundamental challenge facing $ABBV and $CVS investors is patience—the bridge between current depressed trailing multiples and more reasonable forward valuations requires time. However, history suggests that this gap typically closes as earnings normalize and the market reassesses fundamentals without the distortion of one-time charges.

Both companies offer the combination of attractive forward valuations, solid dividend income, and strong market positions that characterize compelling value opportunities. For investors with medium-term horizons and comfort with healthcare sector dynamics, these names merit serious consideration as portfolio additions. The market's current pricing appears to overweight recent disappointments while underweighting normalized earnings power—a classic setup for value creation.

As pharmaceutical and healthcare services companies continue navigating structural industry challenges, those with financial strength, market leadership, and reasonable valuations should emerge as winners. AbbVie and CVS Health fit this profile, suggesting that current prices may offer rare value in an expensive market.